Mouse CD70 / CD27L / TNFSF7 Recombinant Protein (Fc Tag)(Discontinued)
Fig 1: Mouse CD70 / CD27L / TNFSF7 Recombinant Protein (Fc Tag)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 200 µg |
| Purification : | > (12.5+86.3) % as determined by SDS-PAGE. |
| Content : | Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
| Storage condition : | Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| AA sequence : | Gln47-Pro159 |
| Alternative Name : | Cd27l Protein, Mouse; CD27LG Protein, Mouse; Tnfsf7 Protein, Mouse |
Source : HEK293 Cells
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates. Cancer Immunotherapy Co-stimulatory Immune Checkpoint Targets Immune Checkpoint Immune Checkpoint Proteins Immune Checkpoint Targets Immunotherapy Targeted Therapy
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates. Cancer Immunotherapy Co-stimulatory Immune Checkpoint Targets Immune Checkpoint Immune Checkpoint Proteins Immune Checkpoint Targets Immunotherapy Targeted Therapy
1.Measured by its binding ability in a functional ELISA. 2.Immobilized mouse CD27-His at 10µg/mL (100µL/well) can bind mouse CD70 , the EC50 of mouse CD70 is 10-50 ng/mL.
Endotoxin :< 1.0 EU per µg protein as determined by the LAL method.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
